Please assess the completion status of the following clinical trial:

Trial Title: Study of Dapansutrile Capsules in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects 18 years old or older~2. Symptomatic stable HF (NYHA class II-III) with reduced left ventricular ejection fraction (LVEF≤40%, measured within 6 months of enrollment - no changes in cardiac medications or new device implantation within past 2 months)~3. Peak exercise limited by shortness of breath and/or fatigue associated with a respiratory exchange ratio (RER) \> 1.00 (reflecting maximal aerobic effort)~4. Reduced peak aerobic exercise capacity (peak VO2) to less than 80% of predicted value by age/gender at Baseline~5. Plasma CRP or hsCRP levels \> 2 mg/L at Screening~6. Acceptable overall medical condition to be safely enrolled in and to complete the study (with specific regard to cardiovascular, renal and hepatic conditions) in the opinion of the Principal Investigator~7. Ability to provide written, informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Principal Investigator, to understand and comply with all the requirements of the study~Exclusion Criteria:~1. Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential who:~   1. Are or intend to become pregnant (including use of fertility drugs) during the study~  2. Are nursing~  3. Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic \[injectable or patch\] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the study.)~2. Abnormal blood pressure or heart rate response, angina or ECG changes (ischemia or arrhythmias) occurring during CPX~3. Presence or known history of autoimmune conditions (e.g., systemic lupus erythematosus, hypophysitis, etc.)~4. History or evidence of active tuberculosis (TB) infection at Baseline visit or one of the risk factors for tuberculosis such as but not limited or exclusive to:~   1. History of any of the following: residence in a congregate setting (e.g., jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g., injection or non-injection), health-care workers with unprotected exposure to subjects who are at high risk of TB or subjects with TB disease before the identification and correct airborne precautions of the subject or~  2. Close contact (i.e., share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease within the last 12 months.~5. Use of any prohibited concomitant medications/therapies over the periods defined in Section 5.6.3 or planned use of any prohibited concomitant medications/therapies during the Treatment Period~6. Any other concomitant medical or psychiatric condition(s), disease(s) or prior surgery(ies) that, in the opinion of the Principal Investigator, would impair the subject from safely participating in the trial and/or completing protocol requirements, including but not limited to:~   1. physical inability to walk on a treadmill~  2. decompensated HF (edema, NYHA IV)~  3. significant ischemic heart disease, angina~  4. arterial hypotension (blood pressure \[BP\] systolic \< 90 mmHg)~  5. arterial hypertension (resting BP systolic \> 160 mmHg)~  6. atrial fibrillation with rapid ventricular response~  7. severe valvular disease~  8. severe chronic obstructive or restrictive pulmonary disease~  9. moderate-severe anemia (Hgb \< 10 g/dL)~  10. severe diabetic neuropathy or myopathy~7. Active or recent (within 2 weeks) infection prior to the Baseline visit~8. History of or known positive for HIV, Hepatitis B surface antigen or antibodies to Hepatitis C Virus~9. Known history of renal impairment and/or creatinine clearance less than 50 mL/min calculated by Cockcroft-Gault method~10. Active malignancy or recent malignancy with chemotherapy treatment within the past 6 months~11. Enrollment in any trial and/or use of any investigational product or device within the immediate 30-day period prior to the Baseline visit~12. Previous exposure to the investigational product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dapansutrile capsules (Type: EXPERIMENTAL): A total of 8 patients in each cohort will receive dapansutrile capsules:~* Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~* Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days~* Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days
- Placebo Capsules (Type: PLACEBO_COMPARATOR): A total of 2 patients in each cohort will receive placebo capsules:~* Cohort 1 will receive 5 placebo capsules QD for 14 days~* Cohort 2 will receive 5 placebo capsules BID for 14 days~* Cohort 3 will receive 5 placebo capsules QID for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).